Evidence map›Paper›PMID 40620738›Full record

ReviewArchives of medical sciences. Atherosclerotic diseases2025

Optimal dual antiplatelet therapy for coronary artery bypass grafting: a systematic review and meta-analysis.

Ali Salman, Saad Ahmed Waqas, Jazza Aamir, Ruqiat Masooma Batool, Muhammad Khalid Afridi, Fatima Aman Makda, Ifrah Ansari, Haiqa Aamer, Sadaf Iftikhar, Faraz Arshad and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archives of medical sciences. Atherosclerotic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ali SalmanDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Saad Ahmed WaqasDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Jazza AamirDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Ruqiat Masooma BatoolDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Muhammad Khalid AfridiDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Fatima Aman MakdaDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Ifrah AnsariDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Haiqa AamerDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Sadaf IftikharDepartment of Medicine, Akhtar Saeed Medical and Dental College, Lahore, Pakistan.
Faraz ArshadDepartment of Medicine, Shaikh Zayed Hospital, Lahore, Pakistan.
Usama Hussain KamalDepartment of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan.
Rizwana NoorDepartment of Medicine, Khyber Medical College, Peshawar, Pakistan.
Mudassar BaigSunderland Royal Hospital, Sunderland, United Kingdom.
Ashish GuptaSunderland Royal Hospital, Sunderland, United Kingdom.
Ali HasanNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Farhan ShahidAston University, Birmingham, UK.
Raheel AhmedNational Heart and Lung Institute, Imperial College London, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This meta-analysis evaluated the efficacy and safety of dual antiplatelet therapy (DAPT) with aspirin combined with ticagrelor, clopidogrel, or prasugrel in coronary artery bypass grafting (CABG) patients. Methods: Nineteen studies involving 9,585 patients were included. Results: Post-CABG administration of ticagrelor significantly reduced all-cause mortality (OR = 0.49 [0.33, 0.73]; Conclusions: In CABG patients, DAPT with aspirin and ticagrelor offers the best balance between efficacy and safety, improving key outcomes while managing bleeding risk. Prasugrel's increased bleeding risk requires caution in its use.

Indexed as

clopidogreldual antiplatelet therapymajor bleedingprasugrelticagrelor

Identifiers

PMID40620738
PMCPMC12223981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.